| 发明名称 | Recombinant HCV E2 glycoprotein | ||
| 摘要 | The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof. | ||
| 申请公布号 | US9598467(B2) | 申请公布日期 | 2017.03.21 |
| 申请号 | US201313967059 | 申请日期 | 2013.08.14 |
| 申请人 | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED | 发明人 | McCaffrey Kathleen;Drummer Heidi;Poumbourios Pantelis |
| 分类号 | C07K14/005;A61K39/12;A61K39/29;C07K16/10;A61K38/00;A61K39/00 | 主分类号 | C07K14/005 |
| 代理机构 | Foley & Lardner LLP | 代理人 | Foley & Lardner LLP |
| 主权项 | 1. An isolated modified hepatitis C virus (HCV) E2 glycoprotein comprising a modification in the HCV-E2 receptor-binding domain (RBD) ranging from amino acid residues 384 to 661, wherein, in the modified glycoprotein, at least the intergenotypic variable region (igVR) of the HCV-E2 receptor-binding domain is deleted, and wherein the modified glycoprotein binds to the HCV receptor CD81. | ||
| 地址 | Melbourne AU | ||